Evidence map›Paper›PMID 26918067›Full record

ArticleCurrent fungal infection reports2015

Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Brad Moriyama, Sameer Kadri, Stacey A Henning, Robert L Danner, Thomas J Walsh, Scott R Penzak

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current fungal infection reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Observational
  4. Influence of theFrontiers in pharmacology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Brad MoriyamaNIH Clinical Center, Pharmacy Department, Bethesda, MD.
Sameer KadriNIH Clinical Center, Critical Care Medicine Department, Bethesda, MD.
Stacey A HenningNIH Clinical Center, Pharmacy Department, Bethesda, MD.
Robert L DannerNIH Clinical Center, Critical Care Medicine Department, Bethesda, MD.
Thomas J WalshTransplantation-Oncology Infectious Diseases Program, Department of Medicine, Pediatrics, and Microbiology and Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, NY.
Scott R PenzakDepartment of Pharmacotherapy University of North Texas System College of Pharmacy, Fort Worth, TX.
National Institutes of Health Clinical Center · USCornell University · USUniversity of North Texas Health Science Center · US

Funding

Functional Genomics of Inflammation and Critical IllnessZIACL001164 · CLC · CLINICAL CENTER · PI DANNER, ROBERT L · 2009 to 2018
$0k
Preclinical and Clinical Investigations of Severe Infection and Critical Illness ZIACL008060 · CLC · CLINICAL CENTER · PI DANNER, ROBERT L · 2009 to 2025
$0k
Intramural NIH HHS ZIA CL001164
6 · The paper itself

Abstract

Voriconazole is an antifungal triazole that is the first line agent for treatment of invasive aspergillosis. It is metabolized by CYP2C19, CYP2C9, and CYP3A4 and demonstrates wide interpatient variability in serum concentrations. Polymorphisms in CYP2C19 contribute to variability in voriconazole pharmacokinetics. Here, evidence is examined for the use of voriconazole therapeutic drug monitoring (TDM) and the role of CYP2C19 genotyping in voriconazole dosing. The majority of studies exploring the impact of voriconazole TDM on efficacy and safety have found TDM to be beneficial. However, most of these studies are observational, with only one being a randomized controlled trial. High-volume multicenter randomized controlled trials of TDM are currently not available to support definitive guidelines. There is a significant relationship in healthy volunteers between CYP2C19 genotype and voriconazole pharmacokinetics, but this association is markedly less visible in actual patients. While CYP2C19 genotype data may explain variability of voriconazole serum levels, they alone are not sufficient to guide initial dosing. The timeliness of availability of CYP2C19 genotype data in treatment of individual patients also remains challenging. Additional studies are needed before implementation of CYP2C19 genotyping for voriconazole dosing into routine clinical care.

Indexed as

CYP2C19pharmacogenomicspharmacokineticsvoriconazole

Identifiers

PMID26918067
PMCPMC4764088
OpenAlexW2089554833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.